Brokerages predict that Verastem, Inc. (NASDAQ:VSTM) will post earnings of ($0.32) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Verastem’s earnings. The lowest EPS estimate is ($0.35) and the highest is ($0.28). Verastem posted earnings of ($0.21) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 52.4%. The business is expected to issue its next quarterly earnings report on Monday, November 6th.
According to Zacks, analysts expect that Verastem will report full-year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.49) to ($1.25). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.52) per share, with EPS estimates ranging from ($2.15) to ($1.25). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Verastem.
Verastem (NASDAQ:VSTM) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02.
Several analysts have commented on VSTM shares. Zacks Investment Research cut shares of Verastem from a “hold” rating to a “sell” rating in a research note on Saturday. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 target price on shares of Verastem in a research note on Thursday, June 8th. Oppenheimer Holdings, Inc. set a $6.00 target price on shares of Verastem and gave the stock a “buy” rating in a research note on Wednesday, May 10th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $1.50 target price on shares of Verastem in a research note on Wednesday, June 28th. Finally, Cann reaffirmed a “buy” rating and issued a $6.00 target price on shares of Verastem in a research note on Monday, June 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $4.61.
COPYRIGHT VIOLATION WARNING: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/08/14/zacks-analysts-anticipate-verastem-inc-vstm-will-post-earnings-of-0-32-per-share.html.
Verastem (VSTM) traded up 5.4751% during midday trading on Monday, hitting $3.1748. The stock had a trading volume of 221,545 shares. The firm’s market cap is $117.44 million. Verastem has a 12-month low of $1.05 and a 12-month high of $4.67. The stock has a 50-day moving average price of $3.31 and a 200 day moving average price of $2.15.
Several institutional investors have recently made changes to their positions in VSTM. FMR LLC raised its position in shares of Verastem by 32.2% in the fourth quarter. FMR LLC now owns 901,200 shares of the biopharmaceutical company’s stock worth $1,009,000 after buying an additional 219,445 shares during the period. Renaissance Technologies LLC raised its position in shares of Verastem by 13.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,022,200 shares of the biopharmaceutical company’s stock worth $1,145,000 after buying an additional 122,600 shares during the period. TFS Capital LLC bought a new position in shares of Verastem during the first quarter worth $113,000. Howland Capital Management LLC raised its position in shares of Verastem by 16.5% in the second quarter. Howland Capital Management LLC now owns 294,007 shares of the biopharmaceutical company’s stock worth $641,000 after buying an additional 41,616 shares during the period. Finally, OxFORD Asset Management LLP bought a new position in shares of Verastem during the second quarter worth $234,000. Institutional investors own 22.35% of the company’s stock.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Verastem Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Verastem Inc. and related companies.